Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Tuesday

Atossa Therapeutics (NASDAQ:ATOS) is anticipated to announce its earnings results on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Atossa Therapeutics Stock Up 5.4 %

ATOS opened at $0.75 on Monday. The firm has a market cap of $94.83 million, a PE ratio of -3.43 and a beta of 1.20. The business has a fifty day simple moving average of $0.81 and a 200-day simple moving average of $1.12. Atossa Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.31.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ATOS. Ascendiant Capital Markets raised their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a research note on Wednesday, March 12th.

Institutional Trading of Atossa Therapeutics

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE grew its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after purchasing an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.